Vivos Therapeutics issues $5M convertible promissory note for bridge financing

Vivos Therapeutics issued a convertible promissory note for up to $5 million to V-CO Investors 4 LLC dated May 7, 2026, with an initial $500,000 advance to fund operations ahead of an anticipated $5.5 million equity financing. The note carries a 10% bridge financing fee and 15% interest accrues only upon default, with conversion expected by June 30, 2026.